<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812902</url>
  </required_header>
  <id_info>
    <org_study_id>UROUSP - 006</org_study_id>
    <nct_id>NCT01812902</nct_id>
  </id_info>
  <brief_title>Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy</brief_title>
  <acronym>LFD</acronym>
  <official_title>Prospective Randomized Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is currently the second most common cause of cancer death in men in Western
      countries. Lymphadenectomy is the gold standard procedure for staging pelvic lymph node and
      is classically indicated in intermediate and high risk prostate cancer patients and is held
      at the same time of prostatectomy. A traditionally pelvic lymphadenectomy covers the
      obturator chain bilaterally. Recently, some studies have demonstrated the existence of lymph
      node involvement outside the traditional boundaries of classical lymphadenectomy,
      recommending therefore extended dissection; this also includes the external / internal /
      common iliac chains and presacral. Thus lymphadenectomy, according to these authors, would
      also has a therapeutic role, besides helping in better staging. Although some retrospective
      studies report an association between lymphadenectomy and tumor progression, the exact impact
      of extended lymphadenectomy in oncological outcome of patients with prostate cancer is not
      clearly established, mainly by lack of prospective randomized studies on the subject . The
      study objectives are to compare the oncologic results of extended lymphadenectomy versus
      limited in order to elucidate the role of extended dissection in lymph node staging and
      results of treatment in terms of increased tumor cure. The investigators also intend to
      identify patients who may benefit from oncologically extended procedure. To do this, the
      investigators will evaluate prospectively patients diagnosed with prostate cancer at
      intermediate or high risk indicating lymphadenectomy and radical prostatectomy. These
      patients will be randomized to the extended versus limited lymphadenectomy and the
      investigators will compare the lymph node metastasis and pattern of spread of prostate
      cancer, as well as biochemical relapse-free survival, freedom from progression to metastasis
      and cancer-specific survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical relapse-free survival</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Staging</measure>
    <time_frame>One Month</time_frame>
    <description>At the moment of the pathological analysis We will do immunohistochemistry to detect micro metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Spread pattern of prostate cancer</measure>
    <time_frame>One Month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>Ten years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Extended LND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical Prostatectomy with extended lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limited LND</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical Prostatectomy with Limited lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <arm_group_label>Extended LND</arm_group_label>
    <arm_group_label>Limited LND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate Cancer patients with intermediate or high risk and with indication of radical
             prostatectomy and LND

          -  Absence of bone metastasis or other organ imaging test (MRI or scintigraphy)

          -  Absence of hormone treatment

          -  Absence of radiotherapy

          -  Signing an informed consent

          -  Availability and adequacy of lymph node tissue samples to perform the
             immunohistochemical

        Exclusion Criteria:

          -  Life expectancy less than 10 years

          -  Absence of clinical conditions for the procedure

          -  Laparoscopic or perineal surgery

          -  Presence of bone or visceral metastasis

          -  Neoadjuvant treatment

          -  Another malignant neoplasia

          -  Prior abdominal or pelvic surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos F Dall'Oglio, M.D. Phd</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean FP Lestingi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose P Junior, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre C Sant'Anna, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael F Coelho, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuliano B Guglielmetti, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliana N Ravaninni, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daher C Chade, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matheus S Chaib, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricio D Cordeiro, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo R Pessoa, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luiz AA Botelho, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriano Nesralla, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio B Murta, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio L Ortega, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel K Abe, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonardo L Borges, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luiz CN Oliveira, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavio GM Areas, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Marcos Francisco Dall'Oglio</investigator_full_name>
    <investigator_title>M.D. Phd</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Prostate specific antigen</keyword>
  <keyword>lymphadenectomy</keyword>
  <keyword>Limited lymphadenectomy</keyword>
  <keyword>Extended lymphadenectomy</keyword>
  <keyword>Immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

